Frequently expressed glypican‐3 as a promising novel therapeutic target for osteosarcomas

Osteosarcoma (OS) is the most common bone malignancy without a reliable therapeutic target. Glypican‐3 (GPC3) mutation and upregulation have been detected in multidrug resistant OS, and anti‐GPC3 immunotherapy can effectively suppress the growth of organoids. Further profiling of GPC3 mutations and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Jun‐Hua, Yang, Tao, Li, Hong, Li, Sheng, Li, Ting‐Ting, Ye, Hai‐Shan, Lu, Meng‐Di, Chu, Xiao, Zhong, Guo‐Qing, Zhou, Jie‐Long, Wu, Mo‐Li, Zhang, Yu, Liu, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530858/
https://www.ncbi.nlm.nih.gov/pubmed/35946078
http://dx.doi.org/10.1111/cas.15521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530858/
https://www.ncbi.nlm.nih.gov/pubmed/35946078
http://dx.doi.org/10.1111/cas.15521

Ejemplares similares